NCT06829225CompletedPhase 1
Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)
A Phase 1, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-7240 in Healthy Chinese Participants.
Source: ClinicalTrials.gov · Last updated 17 Feb 2025
Brief summary (registry, in English)
The goal of this study is to learn about the safety of tulisokibart in healthy participants and what happens to tulisokibart over time when participants receive treatment intravenously versus subcutaneously.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 11 Feb 2025
- Start date
- 13 Jun 2024
- Primary completion date
- 11 Nov 2024
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Ulcerative colitis
- NCT number
- NCT06829225
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- From 13 Jun 2024 to the primary completion date, 11 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of cancer (malignancy)
Lab values
- Has positive serum test for human immunodeficiency virus (HIV), hepatitis C or hepatitis B virus infection
Who the study is looking for
- Be in good health
- Has a body mass index (BMI) ≥18 and ≤28 kg/m\^2 and weight ≥40.0 kg
- Continuous non-smoker who has not used tobacco or nicotine-containing products for at least 3 months prior to the dosing of study drug
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Third Hospital (Site 0001) Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.